EUROPE – The German company CureVac provided disappointing preliminary results from a clinical trial of its COVID-19 vaccine, dimming hopes that it could help fill the world’s current greatest need. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any COVID-19 vaccine maker. Results released were based on data from 135 volunteers who got sick with COVID-19 as an independent panel compared the number of sick people who had…
Read MoreCureVac’s vaccine proves to have a 47% efficacy rating after its preliminary results
